# Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

> **NCT05090280** · PHASE1 · COMPLETED · sponsor: **Ensysce Biosciences** · enrollment: 111 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** PF614 solution
- **DRUG:** Naltrexone Hydrochloride
- **DRUG:** Nafamostat Mesylate

## Key facts

- **NCT ID:** NCT05090280
- **Lead sponsor:** Ensysce Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2023-04-26
- **Final completion:** 2023-04-26
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2024-09-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05090280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05090280, "Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05090280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*